99¦~01¤ë¸¹ ¹D ªk ªk °T (213)

DEEP & FAR

 

 

«IÅv®×¯A¤Î¤ºÁô¹w´Á°ÝÃD

¤G¡BAstra Aktiebolag v. Andrx Pharm., Inc. (11)

 

 

³¯ºaºÖ ±M§Q¥N²z¤H

¡E¤¤°êÂåÃľǰ|ÃľǨt¾Ç¤h

¡E¤é¥»ºÖ©£¤j¾Ç¥ÍÃľǩҺӤh

¡E¶§©ú¤j¾ÇÂå¾ÇÃIJz©Ò³Õ¤h

 

 

Áp¨¹¦a¤èªk°|§@¬°¨Æ¹êµo²{ªÌ (factfinder) »{©w¦b­ì³B§Î¦¨¤§©T¦³©ÊÃÒ¾Ú¥i¾a¡A¥»°|´N¦¹»{©w¨Ã¥¼µo²{©úÅã¿ù»~¡CÁp¨¹¦a¤èªk°|¨Ã¥¼«j±j±µ¨üCKD»sµ{¥i¦b­ì³B§Î¦¨¤§ÃÒ©ú¡A¦³¦p¤£¦P·N¨£®Ñ©Ò¸ü; ¬Û¤Ï¦a¡AÁp¨¹¦a¤èªk°|¬Û«HCKD »sµ{½T¥i¾É­P¦b­ì³B§Î¦¨¤§ÃÒ¾Ú¡C

¦p¤w¯d·N¡A²ßª¾§Þ³N¤§°Ñ¦Ò¸ê®Æ­Y¥¼©ú¥Õ«ü¥X¯A¤Î¥ô¦ó½Ð¨D¶µ­­¨î±ø¥ó¡A¤]³\¤´µMÄÝ©ó¤ºÁô¤§¹w´Á[1]¡C¦Ó¥B"©T¦³©Ê¤£¤@©w»P¼ô±x¸Ó¶µ§ÞÃÀ¤H¤h¤§³q±`ª¾ÃѦ³¦P¤@©Ê¤§©µ¦ù¤º²[¡C¤@¯ë¼ô±x¸Ó¶µ§ÞÃÀ¤H¤h¥ç¥i¯à¤£»{¥i¸Ó²ßª¾§Þ³N¤§©T¦³©Ê¯S¦â©Î¥\¯à"[2]¡CÁöµMLövgren »P Lundberg ³Õ¤h¥i¯à¥¼»{©w¦bCKD ±M§Q¥Ó½Ð®×©Ò´¦ÅS¤§CKD's ¤èªkA ¦¨¥÷¯S©Ê¥i¾É­P¦b­ì³B§Î¦¨¤ÀÂ÷¼h¡A¦b­ì³B§Î¦¨«YÄÝ©T¦³¡C

¬ö¿ýÅã¥Ü¦b­ì³B§Î¦¨¤ÀÂ÷¼h«YÄÝ©ó²ßª¾§Þ³N¡A§Y¨Ï¸Ó»sµ{·í®É¥¼³Q»{ª¾¡C³æ¿W­«·s»{ª¾¤£¯à¨Ï¸Ó²ßª¾§Þ³N¨ã¦³¥i±M§Q©Ê[3]¡C

¯÷¤ÞÃÒAtlas Powder §P¨Ò"µo²{²ßª¾§Þ³N²Õ¦¨ª«¤§¦­¥ý¥¼¨üª`·N¨ì¤§©Ê½è¡A©Î²ßª¾§Þ³N¥\¯à¤§¬ì¾Ç©Ê¸ÑÄÀ¡A¤£¯à´N¦³²Õ¦¨ª«·s½á¤©µo²{ªÌ¨ä¥i±M§Q©Ê"[4];¥t¦³§P¨Ò¡A¸ÑÄÀ¤wª¾»sµ{¤§³Ìªñµo²{¦¨ªG¤£¨ã¥i±M§Q©Ê¡A¦]¸Óµ¥¦¨ªG«Y¤ºÁô(©T¦³)©ó¤wª¾¤§»sµ{[5];©|¦³§P¨Ò¡A»{©w¤wª¾»sµ{·sÆ[ÂI¤§»{ª¾¡A¨Ã«D·s¿o»sµ{¤§¥i±M§Qµo©ú[6]¡C¦]¦¹¾¨ºÞCKD §_»{¡ALövgren »P Lundberg ³Õ¤h¤w»{ª¾»P¸ÑÄÀ¡ACKD¤§OMP ¤ù¾¯©Ò§Î¦¨¤§¤ÀÂ÷¼h¡A«Y²Õ¦X³Q¦C©ó¤èªkA¬Y¨Ç¦¨¥÷¤§¦ÛµMµ²ªG¡C

 

 

 

 

  



[1] See In re Cruciferous Sprout Litig., 301 F.3d 1343, 1349 (Fed. Cir. 2002)

[2] Id.; Schering Corp. v. Geneva Pharms., 339 F.3d 1373, 1377 (Fed. Cir. 2003) (rejecting the contention that inherent anticipation requires recognition in the prior art). (»é¦^¤ºÁô¹w´Á­n¨D¬°²ßª¾§Þ³N©Ò»{ª¾¤§½×ÂI)

[3] Id.

[4] (citing Atlas Powder, 190 F.3d at 1347)

[5] Bristol-Myers Squibb Co. v. Ben Venue Labs., Inc., 246 F.3d 1368, 1376 (Fed. Cir. 2001)

[6] Verdegaal Bros., Inc. v. Union Oil & Co. of Cal., 814 F.2d 628, 633 (Fed. Cir. 1987)